my personal edition > depression > news
E-Mail this DGReview to a colleague
DGReview
Citalopram Augmented With Carbamazepine In Depression Pilot Study
A DGReview of :"Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study"
European Neuropsychopharmacology
05/15/2002
By Elda Hauschildt
A pilot study suggests carbamazepine augmentation of citalopram therapy could be clinically useful in depressive patients who do not respond to citalopram alone.
Adding carbamazepine can also lead to decreased plasma concentrations of the active enantiomer, escitalopram, according to European researchers who conducted an open study with four outpatients and two inpatients diagnosed with a major depressive episode.
Participants were non-responders to four weeks pre-treatment therapy with citalopram.
Some of the participants had comorbidities. Two patients had phobic anxiety disorder with panic attacks. Others comorbidities noted were generalised anxiety disorder, alcohol abuse, dependent personality disorder and hypertension.
The investigators added carbamazepine during a second four-week drug therapy period.
They report a slight but significant decrease in patient depression scores within one week of adding carbamazepine. Treatment was generally well tolerated. Adverse events included nausea in one patient, diarrhoea in one patient and rash in two.
The researchers found a significant decrease in plasma concentrations of the citalopram eutomer S-citalopram (27 percent) and in R-citalopram (31 percent). They also observed a significant decrease in the ratio S/R-citalopram propionic acid derivative.
European Neuropsychopharmacology, 2002; 12: 255-260.
"Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study"
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
